Ms. Kim is the Chief Executive Officer of E&Investment, Inc., a South Korean venture capital firm specializing in investments in life sciences companies, a position she has held since March 2018. From October 2015 until March 2018, Ms. Kim was a Representative Director for The SEED Investment Co., Ltd. (formerly known as OST Investment Co., Ltd.), a South Korean investment and fund manager specializing in investments in life sciences companies. From January 2015 until December 2017, Ms. Kim served as member of the board of directors of Macrogen, Inc., a South Korean, publicly-traded biotechnology company specializing in precision medicine and biotechnology. Ms. Kim focuses on investment opportunities in several industries, particularly in the field of biopharmaceuticals, and has more than 15 years of experience investing in private equity/venture capital markets. As an investor representative, Ms. Kim has successfully managed more than $400 million in private equity and venture capital funds.
Ms. Kim earned an M.S. and B.S. in biomolecular engineering, as well as an M.B.A. from Yonsei University in Korea.
Mr. Jeong is a Managing Partner with KSV Global Innovations, an innovative growth-focused capital fund he joined in March 2018. He has more than 20 years of experience as a venture capitalist and a financial executive. Prior to joining NeuroBo, from December 2002 to March 2018, Mr. Jeong served as Chief Financial Officer of Rexahn Pharmaceuticals, a NYSE-listed biotechnology company, where he had responsibility for forming strategic alliances and executing license deal in the U.S., Europe and Asia and during which time he completed equity financings totaling more than $150 million. Prior to that, from May 1997 to November 2002, Mr. Jeong was a Senior Investment Manager at Hyundai Venture Investment Corporation (HVIC), where he operated two of the first health care venture capital funds in Korea, with responsibility for more than 51 investments in health technology, information and communications technology and clean technology. While at HVIC, Mr. Jeong realized attractive returns from 31 portfolio companies via IPOs, secondary, sales and acquisitions.
Mr. Jeong earned a B.S. and M.S. in Chemistry from Pohang University of Science & Technology, an M.S. in Finance from Johns Hopkins University, and a Doctor of Management from the University of Maryland.
Mr. Groves has served as Executive Vice President and General Counsel of Medifast, Inc. since November 2011, and as the company’s Corporate Secretary since June 2015. Mr. Groves was a director of the company from 2009 to 2015. He served as an independent director and member of the Audit Committee from 2009 to 2011 and on the Executive Committee from 2011 to 2015. Prior to joining Medifast, from 2003 to 2011, Mr. Groves was Assistant Vice President of Government Affairs for Verizon Maryland, which he joined as a Senior Staff Consultant in 2001. Mr. Groves is a United States Army veteran. He was a direct commissioned Judge Advocate in the United States Army Judge Advocate General’s (JAG) Corp. As a JAG Officer, he practiced law and had the distinction of prosecuting criminal cases in the District Court of Maryland as a Special Assistant United States Attorney. Over the course of three years, he received two Army Achievement Medals, and one Army Commendation Medal.
Mr. Groves is a member of the New Jersey and District of Columbia bars, as well as several bar associations.
Mr. Salsbury is an attorney with nearly 30 years of experience as a senior executive with public and private companies and in private law practice. Since September 2017, Mr. Salsbury has served as Counsel to Verisma Systems, Inc., a provider of cloud-based automated disclosure management systems. From February 2013 to July 2017, he was Secretary and General Counsel to Best Doctors, Inc., a provider of expert medical opinions.
Mr. Salsbury earned a B.A from Dartmouth College and J.D and M.B.A. degrees from the University of Virginia.
Since March 2019, Mr. Oh has served as the President and Chief Executive Officer of JK BioPharma Solutions, a privately-held drug development company focused on early stage developmental assets. Prior to this, he was the Chief Financial Officer of JK BioPharma ctor. ctorFrom August 2001 until December 2016, Mr. Oh held multiple financial positions, ultimately culminating in his role as Vice President of Finance with CD Networks Co., Ltd., a global content delivery network service company.
Mr. Oh earned a B.A. in business administration from Seoul National University.
Mr. Swirsky is President and Chief Executive Officer of publicly traded Rexahn Pharmaceuticals, Inc. In addition to his roles at Rexahn, Mr. Swirsky is currently Chairman of the Board of Cellectar Biosciences, Inc., a publicly traded, clinical stage biopharmaceutical company. He has more than two decades of relevant experience in the biopharmaceutical and healthcare sectors, having served as a director of, or in senior management positions at, a number of publicly held companies over the last 14 years and having provided counsel to corporate clients as a healthcare investment banker. Prior to joining Rexahn in January 2018, from 2013 through its sale to Precigen, Inc. (formerly known as Intrexon Corporation) in 2017, Mr. Swirsky was President and Chief Executive Officer of publicly traded biotechnology company, GenVec, Inc., which he joined in 2006 as Chief Financial Officer. Prior to joining GenVec, Mr. Swirsky worked at Stifel Nicolaus, where he served as a managing director and the head of Life Sciences Investment Banking. Previously, Mr. Swirsky held investment banking positions at UBS, PaineWebber, Morgan Stanley, and Legg Mason.
Mr. Swirsky is a certified public accountant and a CFA® charterholder. He earned a B.S. in Business Administration from Boston University and an M.B.A. from the Kellogg School of Management at Northwestern University.
Dr. Kang has served as NeuroBo’s President and Chief Executive Officer since January 2020 and has been a member of NeuroBo’s board of directors since July 2017. Prior to NeuroBo, he was Co-President and Chief Executive Officer of NeoImmuneTech, Inc., a biotechnology company developing T cell-centered novel immunotherapeutics. Earlier, from January 2013 to February 2019, Dr. Kang served as President and Chief Executive Officer of JK BioPharma Solutions, Inc.
Dr. Kang earned a Ph.D. in Molecular Plant Pathology from The University of Edinburgh, a M.S. in Plant Molecular Genetics from Seoul National University, and a B.S. in Horticultural Science from Seoul National University.